TEST:

therascreen® KRAS RGQ PCR Kit

The therascreen KRAS RGQ PCR Kit is an FDA-approved, qualitative real-time PCR assay manufactured by Qiagen Ltd. for the detection of is intended to detect 7 mutations in codons 12 and 13 of the KRAS gene using DNA extracted from formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) tissue samples. The therascreen® KRAS RGQ PCR Kit is intended to aid in the identification of CRC patients for treatment with Erbitux® (cetuximab) and Vectibix® (panitumumab) based on a KRAS no mutation detected test result.